<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048347</url>
  </required_header>
  <id_info>
    <org_study_id>030019</org_study_id>
    <secondary_id>03-I-0019</secondary_id>
    <nct_id>NCT00048347</nct_id>
  </id_info>
  <brief_title>Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis</brief_title>
  <official_title>An Open-Label, Pilot Study of Type I Interferon (AVONEX) Treatment of Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of the drug interferon-beta1a (AVONEX)&#xD;
      in treating ulcerative colitis and examine the drug's effect on the immune system. People&#xD;
      with ulcerative colitis have increased amounts of inflammatory chemicals (cytokines) made by&#xD;
      immune cells in the lining of the colon. Studies have shown that interferon-beta may block&#xD;
      the activity of these cytokines. Interferon-beta1a (AVONEX) is currently FDA-approved to&#xD;
      treat multiple sclerosis, a disease involving inflammation of the brain and spinal cord.&#xD;
&#xD;
      Patients 18 years of age and older who have had ulcerative colitis for at least 4 months may&#xD;
      be eligible for this study. Candidates will be screened with a review of their medical&#xD;
      records, a medical history and physical examination, electrocardiogram (EKG), blood, urine,&#xD;
      and stool tests, and a pregnancy test for women of childbearing potential. A colonoscopy will&#xD;
      also be done to determine disease activity and extent. This test uses a lighted tube to&#xD;
      examine the amount of inflammation in the colon and take tissue samples (biopsies) for&#xD;
      testing. Before the test, the patient is given a medicine to allay anxiety and the discomfort&#xD;
      of inserting the endoscope into the rectum. This flexible tube allows the doctor to see the&#xD;
      intestinal mucosa and project an image of the inner lining of the intestine onto a TV&#xD;
      monitor. At various places in the intestine, small pieces of tissue are plucked out by a&#xD;
      special device at the tip of the endoscope. The procedure generally lasts 30 minutes to 1&#xD;
      hour.&#xD;
&#xD;
      Participants will come to the NIH Clinical Center once a week for 4 weeks to receive an&#xD;
      injection of interferon-beta, fill out questionnaires, and have a symptoms check, physical&#xD;
      examination, and blood tests. Patients whose colitis has not worsened at the end of the 4&#xD;
      weeks and who have not had significant drug side effects will continue to receive weekly&#xD;
      injections for an additional 8 weeks. Some patients may receive some of the last eight&#xD;
      injections outside of NIH, but all patients will visit the Clinical Center visits every 3 to&#xD;
      4 weeks for a physical exam, symptoms check and blood tests.&#xD;
&#xD;
      After the 12 injections are completed, patients will have another colonoscopy to evaluate the&#xD;
      response to treatment and will return to the Clinical Center every 6 weeks for a total of&#xD;
      four visits, for a physical examination, symptoms check and blood tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to evaluate the immunologic and clinical response to type&#xD;
      I interferon administered to patients with ulcerative colitis. Ulcerative colitis (UC) is a&#xD;
      chronic, relapsing inflammation of the colonic mucosa with major symptoms of diarrhea,&#xD;
      hematochezia, abdominal pain, and an accompanying increase in colorectal carcinoma risk.&#xD;
      Novel approaches to therapy of UC are required because the burden of disease is great (about&#xD;
      500,000 prevalent cases in the United States), standard medical therapy is limited in&#xD;
      effectiveness and toxicity, and surgical therapy, albeit curative, results in permanent&#xD;
      ostomies or complication-prone alternatives.&#xD;
&#xD;
      The rationale for this study is based on the observation that the mucosal inflammation in UC&#xD;
      may be mediated by Th2 cytokines such as IL-4 or cytokines induced along with IL-4. Type I&#xD;
      interferons can block IL-4 receptor signaling by up-regulating cytosolic inhibitory proteins&#xD;
      (suppressor of cytokines signaling or SOCS proteins). Furthermore, two small studies of type&#xD;
      I interferon effects on UC show benefit as opposed to many more studies in Crohn's disease, a&#xD;
      classic Th1 inflammatory disease, which have shown no benefit from type I interferons. We&#xD;
      hypothesize that type I interferons could be used to inhibit the pro-inflammatory signals of&#xD;
      Th2 cytokines in UC.&#xD;
&#xD;
      This study will measure the immunologic and clinical effect of twelve weeks of treatment with&#xD;
      a type I interferon administered to patients with active UC. The primary outcomes include&#xD;
      documenting changes in immune parameters by measuring peripheral and lamina propria&#xD;
      mononuclear cell cytokine release, expression levels of SOCS proteins in mononuclear cells,&#xD;
      and changes in clinical parameters using the Short Clinical Colitis Activity Index and&#xD;
      endoscopic and histologic scores. Secondary endpoints include the rate and severity of&#xD;
      adverse events. Our short-term goal is to correlate changes in immune and biochemical&#xD;
      parameters that accompany or predict clinical responses. The long-term goal of this study is&#xD;
      to establish type I interferons as an effective alternative or adjunctive therapy with a low&#xD;
      risk profile for the treatment of ulcerative colitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The primary endpoint is the percent of patients with a clinical response as defined by a drop in the Short Clinical Colitis Score (SCCAI) of at least 3 points from Week 0 to Week 12. Short Clinical Colitis Score (SCCAI): Bowel frequency(day0-3,night0-2),urgency(0-3),rectal bleeding(0-3),well being(0-4),extracolonic features(0-4), total score 0(best)-19(worst).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Avonex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVONEX</intervention_name>
    <description>30µg IM every week for 12 weeks</description>
    <arm_group_label>Avonex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Age 18 years old or greater.&#xD;
&#xD;
               2. Diagnosis of ulcerative colitis for at least 4 months based on endoscopic&#xD;
                  appearance or radiographic distribution of disease and corroborated with&#xD;
                  histopathology (especially the absence of granulomata).&#xD;
&#xD;
               3. Presence of current active disease as defined by a Simple Clinical Colitis&#xD;
                  Activity Index of greater than or equal to 5 (for either of the two measurements&#xD;
                  done during the Screening Phase and that the second measurement is within 50&#xD;
                  percent of the value of the first) who may or may not have the presence of one of&#xD;
                  the following: current corticosteroid- dependence for disease treatment, disease&#xD;
                  refractory to corticosteroids, or history of intolerance to treatment with&#xD;
                  corticosteroids (for criterion of co-administered corticosteroid dose see below).&#xD;
&#xD;
                  Corticosteroid-dependence is defined as relapse of ulcerative colitis within 60&#xD;
                  days of completing a course of corticosteroid treatment, or during corticosteroid&#xD;
                  tapering at doses greater than or equal to 10 mg prednisone/day (or equivalent),&#xD;
                  or within three months following corticosteroid tapering while receiving a&#xD;
                  steroid dose of greater than or equal to 10 mg prednisone/day (or equivalent).&#xD;
&#xD;
               4. If currently receiving medication for ulcerative colitis, patients may be on a&#xD;
                  stable regimen of one or a combination of the following drug doses and durations:&#xD;
&#xD;
        Corticosteroids (less than or equal to 25 mg Prednisone/d or Prednisone equivalent) is&#xD;
        greater than or equal to 4 weeks;&#xD;
&#xD;
        5-ASA/Sulfasalazine is greater than or equal to 4 weeks;&#xD;
&#xD;
        Azathioprine/6-MP/thioguanine is greater than or equal to 12 weeks. (Note: Patients&#xD;
        receiving azathioprine/6-MP/thioguanine must have been on a stable dose of this medication&#xD;
        for greater than or equal to 8 weeks before randomization);&#xD;
&#xD;
        Probiotics (live bacterial dietary supplements) greater than or equal to 4 weeks;&#xD;
&#xD;
        Prebiotics (dietary supplements to produce biologically active substances) greater than or&#xD;
        equal to 4 weeks.&#xD;
&#xD;
        5. Use of barrier or hormonal methods of birth control for female subjects who are not&#xD;
        surgically sterile or postmenopausal.&#xD;
&#xD;
        6. Negative serum beta-hCG for women of child-bearing potential (women who are not&#xD;
        surgically sterile or postmenopausal) to exclude early unnoticed pregnancy.&#xD;
&#xD;
        7. Negative results on stool examination for culture of enteric pathogens (Salmonella,&#xD;
        Shigella, Yersinia, Campylobacter, Vibrio, E. coli O157/H7), Clostridium difficile toxin&#xD;
        assay, enteric parasites and their ova (including Giardia and Cryptosporidia).&#xD;
&#xD;
        8. Thyroid function test and TSH level within establish normal range set by the Clinical&#xD;
        Center.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Inability to meet any of the above inclusion criteria.&#xD;
&#xD;
          2. Use of any of the following medications within the specified time period prior to the&#xD;
             first dose of interferon-beta or at any time during the study:&#xD;
&#xD;
             Non-steroidal anti-inflammatory agents (including COX-2 inhibitors), - 1 week&#xD;
&#xD;
             Corticosteroids (greater than 25 mg Prednisone/d or Prednisone equivalent),&#xD;
             Methotrexate, Cyclosporin, Tacrolimus, Thalidomide, or Mycophenolate mofetil - 4 weeks&#xD;
&#xD;
             Monoclonal antibodies to TNF alpha or any Other Biologic (cytokine, anti-cytokine, or&#xD;
             integrin-based therapy, for instance) - 4 months&#xD;
&#xD;
             Any experimental agent - 1 month&#xD;
&#xD;
             Concomitant use of any of the following drugs: isoniazid, iproniazid, dantrolene,&#xD;
             ticrynafen (tienilic acid), ibufenac, bromfenac, benoxaprofen, zileutan, nicotinic&#xD;
             acid, trovafloxacin, perhexiline, dilevavol, labetalol, pemoline, felbamate,&#xD;
             tolcapone, diclofenac, AIDS drugs (HIV+ subjects are excluded anyway), and&#xD;
             troglitozone.&#xD;
&#xD;
          3. History of colectomy, partial colectomy, current ostomy, or pouchitis.&#xD;
&#xD;
          4. Presence of significant electrocardiogram abnormalities including QT(c) greater than&#xD;
             or equal to 0.48 sec, Mobitz type II second degree or third degree atrioventricular&#xD;
             block, left bundle branch block or right bundle branch block accompanied by any&#xD;
             fascicular block, changes consistent with acute ischemia or pericarditis.&#xD;
&#xD;
          5. Presence of a diagnosis of Crohn's disease, indeterminate colitis, microscopic&#xD;
             colitis, ischemic colitis, or colitis attributable to infection. This determination&#xD;
             may require use of clinical, endoscopic, and histologic data.&#xD;
&#xD;
          6. Presence of Cushing's syndrome.&#xD;
&#xD;
          7. Presence of current active bowel obstruction, intestinal perforation, significant GI&#xD;
             hemorrhage, known presence of high grade stricture, history of toxic megacolon,&#xD;
             history of colonic epithelium high-grade dysplasia or a dysplasia-associated lesion or&#xD;
             mass that does not resemble an adenoma (that is a mass lesion, stricture, or&#xD;
             broad-based tumor).&#xD;
&#xD;
          8. Anticipation that surgery may be required to treat the ulcerative colitis within 3&#xD;
             months of study entry.&#xD;
&#xD;
          9. HIV positivity or signs and symptoms consistent with HIV infection.&#xD;
&#xD;
         10. Acute systemic or intestinal infection requiring antibiotics.&#xD;
&#xD;
         11. Active hepatitis B or C.&#xD;
&#xD;
         12. Decompensated liver disease (Childs-Pugh class B or C).&#xD;
&#xD;
         13. Hematocrit less than 30 percent&#xD;
&#xD;
             Platelet count 120,000 less than or greater than 850,000&#xD;
&#xD;
             PT INR greater than 1.3 or PTT prolonged by greater than 3 seconds&#xD;
&#xD;
             Serum creatinine or BUN greater than 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
             ALT (SGPT) or AST (SGOT) greater than 2 times the ULN&#xD;
&#xD;
             Total bilirubin greater than 1.25 times the ULN&#xD;
&#xD;
             Alkaline phosphatase greater than 1.5 times the ULN.&#xD;
&#xD;
         14. Pregnancy or nursing (for women).&#xD;
&#xD;
         15. History of cancer (other than resected cutaneous basal or squamous cell carcinoma and&#xD;
             in situ cervical cancer) with less than 5 years' documentation of a disease-free&#xD;
             state.&#xD;
&#xD;
         16. History of a myocardial infarction within the last 12 months.&#xD;
&#xD;
         17. Any other condition that in the investigator's opinion places the patient at undue&#xD;
             risk by participating in the study. This includes but is not limited to: psoriasis,&#xD;
             thyroid disease, myasthenia gravis, lupus erythematosus, rheumatoid arthritis,&#xD;
             Raynaud's disease, autoimmune hepatitis, C1 esterase deficiency or any deficiency of&#xD;
             the complement system, and plasma cell dyscrasias.&#xD;
&#xD;
         18. History of anaphylactic reaction or hypersensitivity to natural or recombinant&#xD;
             interferon-beta, human albumin, or proteins derived from CHO cells/formulation.&#xD;
&#xD;
         19. History of depression with psychotic features, or requiring ECT or hospitalization, or&#xD;
             accompanied by suicidal ideation, gestures, or attempts.&#xD;
&#xD;
         20. History of seizure, except for isolated febrile seizure of childhood.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Mannon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Büschenfelde KH. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999 Jun;44(6):812-8.</citation>
    <PMID>10323882</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>October 29, 2002</study_first_submitted>
  <study_first_submitted_qc>October 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2002</study_first_posted>
  <results_first_submitted>July 6, 2010</results_first_submitted>
  <results_first_submitted_qc>August 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2010</results_first_posted>
  <last_update_submitted>August 30, 2010</last_update_submitted>
  <last_update_submitted_qc>August 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Peter Mannon, M.D./National Institute of Allergy and Infectious Diseases</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Lymphocyte</keyword>
  <keyword>Monocyte</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Th2</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Avonex</title>
          <description>30 µg IM every week for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Avonex</title>
          <description>30 µg IM every week for 12 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI)</title>
        <description>The primary endpoint is the percent of patients with a clinical response as defined by a drop in the Short Clinical Colitis Score (SCCAI) of at least 3 points from Week 0 to Week 12. Short Clinical Colitis Score (SCCAI): Bowel frequency(day0-3,night0-2),urgency(0-3),rectal bleeding(0-3),well being(0-4),extracolonic features(0-4), total score 0(best)-19(worst).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Avonex</title>
            <description>30 µg IM every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI)</title>
          <description>The primary endpoint is the percent of patients with a clinical response as defined by a drop in the Short Clinical Colitis Score (SCCAI) of at least 3 points from Week 0 to Week 12. Short Clinical Colitis Score (SCCAI): Bowel frequency(day0-3,night0-2),urgency(0-3),rectal bleeding(0-3),well being(0-4),extracolonic features(0-4), total score 0(best)-19(worst).</description>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Avonex</title>
          <description>30 µg IM every week for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <description>Patients reported fever (63%) and mild flu-like symptoms (myalgias in 31%) after injections, but these were transient (usually resolving 4-5 hours after the injection) and responded well to treatment with acetominophen.</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>C. difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>paresthesias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>palmar xeroderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>While this study was designed as a proof-of-concept pilot trial to correlate changes in IL-13 and other cytokines with clinical response, efficacy was measured. The efficacy estimate is limited by the open-label design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Mannon, MD</name_or_title>
      <organization>NIAID</organization>
      <phone>205-934-4726</phone>
      <email>pmannon@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

